Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology · 2025
Effect of trazodone on heart rate, heart rate variability, and QT-intervals in dogs.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silvia V T, DeFrancesco T C, Love K R, Tou S P, Keene B W
Аннотация
INTRODUCTION/OBJECTIVES: To determine the effect of trazodone and placebo on heart rate (HR), heart rate variability, and QT intervals in dogs after oral administration of trazodone or placebo.
ANIMALS, MATERIALS AND METHODS: Twenty healthy adult client-owned dogs were included in the study. Dogs were randomized in a double-blind, placebo-controlled crossover trial. Dogs received trazodone (6 mg/kg q 8 h) or placebo for 24 h, during which a 24-h ambulatory electrocardiogram (ECG) (Holter) was recorded. Diagnostic ECGs and clinician-assessed behavior scores were obtained before and after the 24-h study period. Owners also scored the dog's behavior changes during each of the 24-h study periods. Following a minimum one-week washout period, dogs received the alternate study drug, and all procedures were repeated. Linear and mixed models were used for statistical analyses.
RESULTS: Dogs receiving trazodone had higher average HRs (P=0.035), higher minimum HRs (P<0.001), and reduced HR variability parameters (P<0.001) on the Holter recordings. Electrocardiogram-derived QT interval was not different between groups. Dogs receiving trazodone appeared calmer based on owner assessments (P<0.001) and behavior scores (P=0.006).
STUDY LIMITATIONS: Blood pressure and trazodone blood levels were not measured, making it impossible to determine the effect of these variables on the HR and ECG findings.
CONCLUSIONS: Trazodone increased HR and decreased HRV. Possible explanations include a previously described anticholinergic effect or a possible decrease in blood pressure causing a reflex response. No demonstrable effect on QTi was identified in this cohort of healthy dogs using standard trazodone dosing.
ANIMALS, MATERIALS AND METHODS: Twenty healthy adult client-owned dogs were included in the study. Dogs were randomized in a double-blind, placebo-controlled crossover trial. Dogs received trazodone (6 mg/kg q 8 h) or placebo for 24 h, during which a 24-h ambulatory electrocardiogram (ECG) (Holter) was recorded. Diagnostic ECGs and clinician-assessed behavior scores were obtained before and after the 24-h study period. Owners also scored the dog's behavior changes during each of the 24-h study periods. Following a minimum one-week washout period, dogs received the alternate study drug, and all procedures were repeated. Linear and mixed models were used for statistical analyses.
RESULTS: Dogs receiving trazodone had higher average HRs (P=0.035), higher minimum HRs (P<0.001), and reduced HR variability parameters (P<0.001) on the Holter recordings. Electrocardiogram-derived QT interval was not different between groups. Dogs receiving trazodone appeared calmer based on owner assessments (P<0.001) and behavior scores (P=0.006).
STUDY LIMITATIONS: Blood pressure and trazodone blood levels were not measured, making it impossible to determine the effect of these variables on the HR and ECG findings.
CONCLUSIONS: Trazodone increased HR and decreased HRV. Possible explanations include a previously described anticholinergic effect or a possible decrease in blood pressure causing a reflex response. No demonstrable effect on QTi was identified in this cohort of healthy dogs using standard trazodone dosing.